Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …

Introduction Several targetable genetic alterations have been identified in non-small cell
lung cancers (NSCLC) and drugs targeting these alterations have been approved for the …

Purpose: HER2-targeted therapy is not standard of care for HER2-positive non–small cell
lung cancer (NSCLC). This phase II study investigated efficacy and safety of the HER2 …

Antibody-drug conjugates (ADCs) are rapidly establishing their place and have shown
promising preliminary data in lung cancer with impressive response rates and survival …

PURPOSE HER2 is a critical gene that drives various solid tumors in addition to those of
breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC) …

Lung cancer is a highly heterogeneous disease often driven by well-characterized driver
mutations. Although the best studied are common alterations in the epidermal growth factor …

The increasing number of approved drugs along with next generation sequencing (NGS)
technologies look out as potential revolution of biomolecular characterization of non-small …

Lung cancer remains the leading cause of cancer-associated mortality worldwide, but with
the emergence of oncogene targeted therapies, treatment options have tremendously …

The identification of driver mutations in epidermal growth factor receptor, anaplastic
lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical …

HER2 activating mutations act as oncogenic drivers in various cancer types. In the clinic,
they can be identified by next generation sequencing (NGS) in either tumor biopsies or …